Cycle on Aug 30, 2026

I will begin the research cycle by listing the open threads and watches for this topic to see what specific questions or triggers need to be addressed.

I will search for the status of the Nancy Grace Roman Space Telescope launch, which was scheduled for August 30, 2026, to see if it occurred or was rescheduled.

I will search more specifically for the launch outcome of the Nancy Grace Roman Space Telescope, since August 30, 2026 is today (and current time is 22:40 UTC, which is late afternoon/evening ET). The launch was targeted for 7:26 a.m. Eastern (11:26 UTC) on August 30, 2026. Let's search to see if it launched successfully.

I will fetch the NPR article and the spacepolicyonline.com article to get the exact details of the successful launch of the Nancy Grace Roman Space Telescope, so I can write a detailed finding and resolve the relevant watch.

I have successfully verified that the Nancy Grace Roman Space Telescope has launched. This resolves the watch with ID `019fb013-39c2-71d8-932b-66e49c963e6a`. Let's record the event first. Then I will write a note about the launch. But first, let's search for other news in science and health to see what else has happened recently. I want to check for other active watches or major news. Let's see: 1. ITM Isotope Technologies Munich CRL / NDA resubmission. 2. Definium Phase 3 Panorama trial readout of DT120 in GAD. 3. H5N1 avian flu in Australia/New Zealand. 4. Any other major science/health news. Let's search for recent news in clinical trials, FDA approvals, space, etc. from the past week. Let's do a broad search or check some specific terms. Let's search for "FDA approval" or "Phase 3 clinical trial" with `sort="recent"` and `freshness="week"`.

Now I will search for other recent clinical trials or FDA news. Let's search for "FDA approval" or "Complete Response Letter" or "Phase 3 trial" or "Phase III trial" or "clinical trial results" in the last week.

Let's look into the other watches. For example, there is a watch: - `01a0079b-2493-7ec5-b616-680631330a60`: "Definium Phase 3 Panorama trial readout of DT120 in GAD" expected in September 2026. - `019f1ab9-37ce-758f-a72b-8d16fad8f514`: "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts" expected by the end of 2026. - `019f3ec3-9518-7baa-a4e4-19e437e0557f`: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" expected in Q3 2026. - `019ef6aa-0088-716a-a75d-6adbc6f4984d`: "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" expected in Q3 2026. - `019ed7c8-8ce2-7ba0-9576-f823526d0677`: "uniQure BLA submission for AMT-130 in Huntington's disease" targeted for Q3 2026. - `019ef183-efef-70f6-9f55-cbbd11c943bb`: "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" targeted for late September 2026. - `019f1ab8-f9db-7f35-b537-f4db6a56efeb`: "FDA finalization and launch of Expedited-IND Pilot Program" expected by September 30, 2026. - `01a04564-e836-7517-8d40-771bcd125f8f`: "FDA public hearing on therapeutic use of psychedelic drugs" on September 14, 2026. - `01a030ca-8bbc-74d9-aad8-2f305e2757e3`: "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" expected by September 30, 2026. Let's check if there are any updates on: - Definium DT120 - Vera Therapeutics ORIGIN 3 / atacicept - GondolaBio PORT-77 PATHWAY - uniQure AMT-130 - MoonLake sonelokimab Hidradenitis Suppurativa - Scholar Rock apitegromab - ITM Isotope Technologies Munich ITM-11 CRL / resubmission (CRL was in August 2026) - Xspray Pharma Dasynoc resubmission (watch `01a030ca-9697-72f4-addf-96043b43eb73`) - Sobi NASP uncontrolled gout resubmission (watch `019f1ab8-b786-7130-9ce1-ccf00ee61d03`) Let's perform a web search on "Definium" "DT120" or "Definium Therapeutics" to see if there is any new clinical trial data or news.

Ah! Definium Therapeutics announced positive topline results from its Phase 3 "Voyage" study of DT120 in Generalized Anxiety Disorder (GAD). Let's fetch the actual press release or news articles about this. Let's fetch the Definium press release first to get the exact data points, dates, and quotes. This is a major clinical trial readout! The URL is: https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder or we can fetch a news article like BioPharma Dive or FierceBiotech. Let's do a search to see if we can fetch the press release or FierceBiotech. Let's search again with specific terms to see if we can fetch it or just fetch the FierceBiotech link. Let's fetch the FierceBiotech link. Wait, what is the exact URL of the FierceBiotech article? Let's search for "Definium hits another ph. 3 homerun with anxiety 'sea change' for anxiety" to get the URL.

I will fetch the FierceBiotech article on Definium's Phase 3 GAD trial readout. This is a very important development for Definium's DT120 ODT (lysergide/LSD). Let's fetch it.

This is a fantastic update. Let's see what else has happened. Definium's Phase 3 Voyage study of DT120 (lysergide/LSD ODT) in GAD was positive. - Reduced HAM-A score at week 12 by 11.6 points vs 6.2 points for placebo (a 5.4-point placebo-adjusted change). - This follows positive Phase 3 depression results in June 2026. - The next test is the "Panorama" trial in GAD, set to read out next month (September 2026), which includes a low-dose arm to prevent functional unblinding. Wait! I should write a finding for this. The slug `definium-dt120-phase-3-gad-and-low-dose-mdd-trial-readouts` could be used, or is there a more specific slug? Let's check the existing notes using `read_notes` to see if there is an existing note about Definium. Let's do that right now.

Ah, I see that we have a note with the slug `definium-dt120-lysergide-phase3-trials`. It was updated yesterday. Wait, let's see if there is any other new development. Let's check the status of some of the other things. - uniQure AMT-130 Huntington's disease BLA submission. The watch is "Monitor uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026." - Vera Therapeutics ORIGIN 3 trial. - MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa. - Scholar Rock apitegromab BLA in SMA. - Sobi NASP BLA resubmission. - Xspray Pharma Dasynoc resubmission. - GondolaBio PATHWAY trial. - What about the ISS Russian Zvezda module air leaks? Let's search for "ISS Zvezda module" or "Zvezda leaks" or "Roscosmos NASA Zvezda" to see if there are any new updates. - What about the H5N1 bird flu in Australia or New Zealand? Let's check for any updates. - What about the DRC Ebola outbreak? Let's search for "Ebola" or "Bundibugyo" or "DRC Ebola". Let's do a web search on uniQure AMT-130 to see if they submitted the BLA. Q3 2026 is July-September 2026. Since we are on August 30, 2026, let's see if there is any news about uniQure's BLA submission or if they are still on track or if it has been submitted.

Okay, uniQure plans to release 4-year phase 1/2 data in September 2026 and file the BLA in Q3 2026. Let's watch for that. The BLA has not been submitted yet as of August 30, 2026, but is planned for Q3 (which ends in September). Let's search for "Vera Therapeutics ORIGIN 3" or "atacicept eGFR" to see if there are any new updates on the confirmatory eGFR results.

Ah! Let's fetch the BioSpace article: "Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact" to see if there are new details about the eGFR data. It says "Guggenheim Securities told investors in an Aug. 14 note... patients on Vera's drug showed 'impressive' stabilization in estimated glomerular filtration rate (eGFR) through 52 weeks... the finalized analysis of ORIGIN 3 is up for presentation at a medical congress later this year." Let's fetch this BioSpace page to read more. It might be a valuable update to our existing note `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` or `vera-therapeutics-trutakna-fda-accelerated-approval-igan` (wait, there are two similar slugs here, let's check which one is the correct one. In the prior findings, we have: - `vera-therapeutics-trutakna-fda-accelerated-approval-igan` (score 0.41, updated at 2026-08-30 07:10:33) - `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` (score 0.30, updated at 2026-08-30 07:10:30) Wait, the list of notes from `read_notes` showed: - `vera-therapeutics-trutakna-fda-accelerated-approval-igan` - `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` Ah, there are indeed two. We can update one of them, preferably `vera-therapeutics-trutakna-fda-accelerated-approval-igan` or consolidate them if necessary. Let's fetch the BioSpace article first.

This is a very important update on Vera Therapeutics' Trutakna (atacicept). The FDA released the Summary Basis for Approval document for Trutakna on Thursday, August 13, 2026, which revealed "promising" and "impressive" stabilization in estimated glomerular filtration rate (eGFR) through 52 weeks in the Phase 3 ORIGIN 3 study, matching the profile of Otsuka's Voyxact (sibeprenlimab). This has reassured investors who were worried that Voyxact would have a monopoly on clear eGFR stabilization. Wait! Let's check if there are other watches that we can resolve or update. Let's search for "GondolaBio" "PORT-77" or "PATHWAY" to see if the Phase 2b/3 PATHWAY trial in EPP has been initiated. EPP is Erythropoietic Protoporphyria. Let's do a search.

Let's search for "GondolaBio" and "PATHWAY" to see if there is any mention of a Phase 2b/3 trial or PATHWAY trial starting.

Ah! BridgeBio's Q2 2026 Earnings Call on August 19, 2026, mentions: "And following a productive End-of-Phase-2 meeting with the agency, we would be initiating a Phase 2b/3 study in Q3 of this year." Let's fetch the BridgeBio Q2 2026 earnings call transcript to verify if GondolaBio (which is a BridgeBio spinout or portfolio company) has initiated or is about to initiate the Phase 2b/3 trial (PATHWAY) of PORT-77 in EPP/XLP. Let's do a search on "BridgeBio" "GondolaBio" "PORT-77" "Phase 2b/3" or "initiating" in August 2026.

Ah! The search budget is spent. That's a helpful constraint. I have plenty of solid information to write up our findings and resolve/update watches. Let's review the watches and threads we need to record or update: 1. **Nancy Grace Roman Space Telescope Launch**: We confirmed that the telescope launched successfully on August 30, 2026, at 7:26 a.m. EDT aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center. It is now on a 90-day commissioning period on its way to L2. This resolves the watch `019fb013-39c2-71d8-932b-66e49c963e6a`. 2. **Definium's DT120 GAD Phase 3 Voyage trial readout**: Definium announced positive Phase 3 results for DT120 (lysergide ODT) in GAD on August 12, 2026, showing a highly significant 5.4-point placebo-adjusted reduction on the HAM-A scale at week 12 (11.6 point reduction for DT120 vs. 6.2 points for placebo). This is their second Phase 3 victory (following MDD in June 2026). The next trial "Panorama" is expected to read out in September 2026. This relates to the watch `019f1ab9-37ce-758f-a72b-8d16fad8f514` (which was for GAD and MDD readouts by end of 2026—the Voyage readout is now delivered) and `01a0079b-2493-7ec5-b616-680631330a60` (the low-dose Panorama trial). Wait, since we have the watch `019f1ab9-37ce-758f-a72b-8d16fad8f514` "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts", we can record an event for it (it is ongoing or one_shot? It is `one_shot` but let's see if we should resolve it or if we should record an event). Wait, let's look at `list_threads` output: `019f1ab9-37ce-758f-a72b-8d16fad8f514` is a `one_shot` watch titled "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts" with trigger "Fires when Definium reports topline results for DT120 in GAD or low-dose MDD Phase 3 trials." And there is also `01a0079b-2493-7ec5-b616-680631330a60`, which is a `one_shot` watch titled "Definium Phase 3 Panorama trial readout of DT120 in GAD" expected in September 2026. Let's record an event on `019f1ab9-37ce-758f-a72b-8d16fad8f514` since the Voyage GAD results have read out. Let's resolve it or keep it open? Since it says "topline results for DT120 in GAD or low-dose MDD", and the GAD Voyage trial has read out, we can resolve it or keep it open if there are more trials. Let's resolve it with a note. 3. **Vera Therapeutics' Trutakna (atacicept)**: The FDA released the Summary Basis for Approval document on August 13, 2026, which revealed that in the Phase 3 ORIGIN 3 study, patients on Trutakna showed "impressive" stabilization in estimated glomerular filtration rate (eGFR) through 52 weeks, matching the profile of Otsuka's Voyxact (sibeprenlimab). This has reassured investors concerned about competitor differentiation. This is a very important update that relates to the watch `019f3ec3-9518-7baa-a4e4-19e437e0557f` "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" expected in Q3 2026. Since the eGFR results were released in the FDA approval documents, we can record an event on `019f3ec3-9518-7baa-a4e4-19e437e0557f`. Let's check if the watch is resolved or if the finalized analysis is still pending presentation at a medical congress later this year. The BioSpace article says: "the finalized analysis of ORIGIN 3 is up for presentation at a medical congress later this year." So the watch can remain open or we can record an event on it. Let's record an event with `resolves: false` since the full finalized analysis presentation is still to come. Let's write the findings first. We have: 1. **Nancy Grace Roman Space Telescope Launch**: Let's create a new note for this. Wait, is there a prior note on this? Let's check our `read_notes` list. There is no prior note on the Roman Space Telescope in the list of notes returned by `read_notes`. So we can write a fresh note. Let's choose a durable slug like `nasa-nancy-grace-roman-space-telescope-launch`. 2. **Definium GAD Phase 3 Voyage Readout**: There is an existing note with slug `definium-dt120-lysergide-phase3-trials`. Let's update it with the new findings from the Voyage trial and the upcoming Panorama trial. 3. **Vera Therapeutics' Trutakna eGFR Data**: There are two existing notes: - `vera-therapeutics-trutakna-fda-accelerated-approval-igan` - `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` Let's update `vera-therapeutics-trutakna-fda-accelerated-approval-igan` with the new eGFR details from the FDA Summary Basis for Approval document released on August 13, 2026. Let's check the content of `definium-dt120-lysergide-phase3-trials` first to see what it has so we can write a clean, comprehensive update. Wait, I can't search or fetch now because my search budget is spent, but I can read the notes if I haven't already. Wait, `read_notes` returned a preview: "On August 12, 2026, Definium Therapeutics announced positive topline results from its Phase 3 Voyage study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults with..." Ah, so the note `definium-dt120-lysergide-phase3-trials` was already updated with the Voyage study results in a previous cycle or is already present. Let's double check if we need to update it or if we should write a finding for the Roman Space Telescope launch and the Vera Therapeutics eGFR data. Let's write a note for the Roman Space Telescope launch first. Wait, let's look at the instructions: - "Every substantive finding must: name and link the actual thing (the story, article, paper, or page that was posted/published) — not just 'the discussion'" - "carry 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from (an HN comment permalink, the article URL, etc.)" - "then say what it means." Let's write the note for the Nancy Grace Roman Space Telescope launch. Slug: `nasa-nancy-grace-roman-space-telescope-launch` Title: NASA's Nancy Grace Roman Space Telescope Successfully Launches on Cosmic Mission Let's draft the body: We'll quote from the SpacePolicyOnline article: "Roman lifted off atop a SpaceX Falcon Heavy rocket at 7:26 am ET from Kennedy Space Center, FL." "The launch was completely successful and the telescope is now in a 90-day commissioning period on its way to L2. The solar panels deployed soon after separation from the rocket and communications were established with the Deep Space Network antenna in Canberra, Australia." And from NPR: "The Nancy Grace Roman Space Telescope, which is about the size of a tour bus, lifted off at 7:26 a.m. 'The ride was magnificent. It put us right where we wanted to be.'" Let's write the note `nasa-nancy-grace-roman-space-telescope-launch`.

Now let's look at the Vera Therapeutics Trutakna (atacicept) eGFR data. We have the existing note `vera-therapeutics-trutakna-fda-accelerated-approval-igan`. Let's update it with the new findings from the FDA Summary Basis for Approval document released on August 13, 2026. Wait, let's look at the other slug `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` as well. Since we have two notes, let's update `vera-therapeutics-trutakna-fda-accelerated-approval-igan` and we can redirect or mention both. Actually, let's update `vera-therapeutics-trutakna-fda-accelerated-approval-igan` as the primary note and we can merge the information. Let's write the note. Wait, let's read the current contents of `vera-therapeutics-trutakna-fda-accelerated-approval-igan` first if possible? I don't have a tool to read the note body directly, but I can write to it. I can use the existing information in the preview and the new information from the BioSpace article. The preview of `vera-therapeutics-trutakna-fda-accelerated-approval-igan` says: "On July 7, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary..." Let's write a comprehensive update to `vera-therapeutics-trutakna-fda-accelerated-approval-igan` reflecting both the accelerated approval in July 2026 and the newly disclosed eGFR data from the FDA Summary Basis for Approval document in August 2026. This is a perfect example of a "living set" of findings. Let's do that.

Let's record events on the threads/watches: - `019f3ec3-9518-7baa-a4e4-19e437e0557f`: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" Wait, this is an ongoing or one_shot watch? It is `one_shot` with a fire date of September 30, 2026. Since the official presentation of the full finalized analysis at a medical congress is still pending later this year (even though we got the interim/preliminary eGFR data from the FDA approval package), we can record an event but set `resolves: false` or we can resolve it if the main trigger was the results. Let's look at the description: "Monitor the readout of the confirmatory eGFR kidney function data from Vera Therapeutics' Phase 3 ORIGIN 3 trial of Trutakna (atacicept) in primary IgA nephropathy, expected in Q3 2026." Since the FDA Summary Basis for Approval document released in August 2026 disclosed these results, the data is now public. Let's resolve it with `resolves: true`. Let's call `record_event`.

Now let's check if there are other watches we can resolve or record. Let's see: - `019f1ab9-37ce-758f-a72b-8d16fad8f514`: "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts" Wait, this watch was for: "Monitor the topline readouts of Definium's two Phase 3 trials in generalized anxiety disorder (GAD) and its low-dose Phase 3 trial in major depressive disorder (MDD) for DT120, expected by the end of 2026." Since the first Phase 3 GAD trial (Voyage) has read out with positive results on August 12, 2026, let's record an event. But since the low-dose MDD trial and the second GAD trial (Panorama) are still pending, let's keep it open (`resolves: false`) or check if we should resolve it. Actually, `019f1ab9-37ce-758f-a72b-8d16fad8f514` is a `one_shot` watch. Let's record an event with `resolves: false` since the remaining trials are still to read out. Or wait, let's see. The title is "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts" and description says "two Phase 3 trials in GAD and its low-dose MDD trial". Since only one of the GAD trials (Voyage) has read out, let's keep it open and set `resolves: false`. Let's record an event.

Let's review if there are other watches that have fired or need updates. - `019fb013-39c2-71d8-932b-66e49c963e6a`: "Launch of NASA's Nancy Grace Roman Space Telescope" We already recorded an event for this with `resolves: true` which successfully resolved it. Wait, let's call `resolve_thread` on the thread `019fb013-39c2-71d8-932b-66e49c963e6a` to make sure it's formally marked as resolved by this cycle. Wait, `list_threads` showed it as a thread of kind `watch`. Let's resolve it. Wait, `resolve_thread` requires `thread_id` and `cycle_id`. Let's call it on the Roman Space Telescope watch.

Let's resolve the other watch we completed as well: - `019f3ec3-9518-7baa-a4e4-19e437e0557f`: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" We recorded an event with `resolves: true` on `019f3ec3-9518-7baa-a4e4-19e437e0557f`. Let's call `resolve_thread` on it to mark it resolved.

Let's double-check if there are any other threads or watches we should resolve or record. We have: - `019ef6aa-0088-716a-a75d-6adbc6f4984d`: "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" BridgeBio's earnings call on August 19, 2026, confirmed that they plan to initiate the Phase 2b/3 study (PATHWAY) in Q3 of this year. Since Q3 2026 is still ongoing (July-September) and they haven't announced the official first patient dosed or formal initiation yet (they said "would be initiating"), the watch is still active. Let's keep it open and we don't need to resolve it yet. Are there any other new notes to write? I have written: 1. `nasa-nancy-grace-roman-space-telescope-launch` (New note) 2. `vera-therapeutics-trutakna-fda-accelerated-approval-igan` (Updated note) Let's check if there are any other major news items we should write about. We checked the latest news and found that: - Definium's GAD trial results were announced on August 12, 2026, but that was already documented in the note `definium-dt120-lysergide-phase3-trials` updated yesterday (August 29, 2026). So we don't need to write a duplicate note on that. - We have a very clean set of updates. I will now call `finish_cycle` to complete this research cycle.

I have completed the research cycle for this topic. Here is a summary of the findings and updates from this cycle: ### 1. Successful Launch of NASA's Nancy Grace Roman Space Telescope On **August 30, 2026**, NASA's next-generation **Nancy Grace Roman Space Telescope** successfully launched at 7:26 a.m. EDT aboard a SpaceX Falcon Heavy rocket from the Kennedy Space Center. * **Current Status:** The launch was completely successful, and the telescope has successfully deployed its solar arrays and established communications with the Deep Space Network. It is now on a 90-day commissioning journey to join the James Webb Space Telescope at the Sun-Earth Lagrange point 2 (L2). * **Significance:** Roman has a field of view 100 times larger than Hubble's and will transmit 1.4 terabytes of data daily (compared to JWST's 50–60 gigabytes). It is designed to survey the sky at unprecedented speeds to explore dark matter, dark energy, and discover thousands of new exoplanets. * **Watch Resolution:** Formal watch `019fb013-39c2-71d8-932b-66e49c963e6a` has been successfully resolved. * **Note Recorded:** [[nasa-nancy-grace-roman-space-telescope-launch]] ### 2. Promising eGFR Kidney-Preservation Data Disclosed for Vera Therapeutics' Trutakna Following the accelerated approval of Vera's **Trutakna (atacicept)** in July 2026, the FDA released its official **Summary Basis for Approval** document on **August 13, 2026**. * **Key Findings:** The documents disclosed highly encouraging kidney function preservation data from the pivotal Phase 3 ORIGIN 3 study. Patients treated with Trutakna demonstrated "impressive" and "promising" stabilization of estimated glomerular filtration rate (eGFR) through 52 weeks, matching the competitive profile of Otsuka's Voyxact (sibeprenlimab). * **Significance:** This disclosure significantly de-risks Trutakna's long-term competitive position against Voyxact and reassures investors who were concerned about the drug's ability to compete on kidney function preservation. * **Watch Resolution:** Formal watch `019f3ec3-9518-7baa-a4e4-19e437e0557f` has been successfully resolved. * **Note Updated:** [[vera-therapeutics-trutakna-fda-accelerated-approval-igan]] ### 3. Definium Therapeutics Progresses on Psychedelic GAD Program * **Voyage Trial Victory:** Definium's Phase 3 Voyage trial of **DT120 (lysergide/LSD ODT)** in generalized anxiety disorder (GAD) met its primary endpoint on August 12, 2026, showing a 5.4-point placebo-adjusted reduction on the HAM-A scale at week 12 (11.6 point reduction for DT120 vs. 6.2 points for placebo). * **Next Steps:** Definium is currently running the Phase 3 Panorama trial, which includes a low-dose arm to mitigate the effects of functional unblinding. This trial is expected to read out in **September 2026**. * **Watch Status:** Formal watch `019f1ab9-37ce-758f-a72b-8d16fad8f514` was updated to reflect this first Phase 3 GAD victory, but remains open pending the remaining low-dose MDD and Panorama trial readouts.